Abstract
Ischemia/reperfusion injury (IRI) has long been an area of concern and focus of investigations. Erythropoietin (EPO) exhibits multiple protective effects, and selenium is an antioxidant trace element in the body; however, there have been no reports concerning the effects of EPO combined with sodium selenite on IRI. In the present study, a mouse model of renal IRI (RIRI) was pre‑treated with EPO and sodium selenite to determine the most appropriate combination ratio of the two for further investigation. The results revealed that EPO and sodium selenite had synergistic protective effects in RIRI. EPO was identified as the predominant treatment component, with sodium selenite serving as an adjuvant, and combination treatment was markedly more effective, compared with treatment with either drug alone. The optimal ratio of treatment was 10:1 (10 IU EPO: 1 µg sodium selenite). The results indicated that RIRI markedly induced renal injury, as evidenced by elevated levels of blood urea nitrogen (BUN), as well as higher pathological scores. Pre‑treatment with EPO and sodium selenite significantly decreased serum expression levels of BUN and malonaldehyde (MDA), and increased the expression levels of superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) and nitric oxide (NO), compared with the model group. Furthermore, co‑treatment upregulated PI3K protein expression. Together, the results suggested that co‑administration of EPO and sodium selenite effectively ameliorates IRI‑induced renal injury by reducing oxidative stress and activating the PI3K/NO signaling pathway.
Introduction
Renal ischemia/reperfusion injury (RIRI) is a critical clinical condition often encountered during major surgeries, organ transplantation, or following hypovolemic shock. The pathophysiology involves a complex interplay of oxidative stress, inflammatory responses, and cellular apoptosis triggered by the restoration of blood flow to previously ischemic tissue. While Erythropoietin (EPO) is recognized for its cytoprotective and anti-apoptotic properties, and sodium selenite (Se) is a potent antioxidant, monotherapies often fail to address the multi-faceted nature of RIRI. This study investigates the potential synergistic effects of combining these two agents to enhance renal protection.
Methodology
The research was conducted in two primary phases:
- Optimization Phase: Using 60 Kun-Ming mice, the researchers employed a Uniform Design and Weighted Modification Analysis to identify the most effective ratio of EPO to sodium selenite. The primary endpoint for this phase was the reduction of Blood Urea Nitrogen (BUN) levels.
- Validation and Mechanistic Phase: Using 70 Sprague-Dawley rats, the optimized 10:1 ratio (10 IU EPO: 1 µg Se) was tested. RIRI was induced by clamping the renal pedicle for 60 minutes, followed by 4 hours of reperfusion.
Biochemical markers including BUN, MDA (a marker of lipid peroxidation), and antioxidant enzymes (SOD, GSH-Px) were measured. Histopathological analysis and immunohistochemistry for PI3K expression were also performed to elucidate the underlying signaling pathways.
Results and Discussion
Synergistic Reduction of Kidney Injury Markers
The study successfully identified a synergistic "1+1 > 2" effect when EPO and sodium selenite were combined. As shown in Figure 1, the induction of RIRI (Model group) led to a sharp increase in BUN levels, indicating significant renal dysfunction. While EPO or Se alone showed limited efficacy in this specific model, the combination treatments—particularly at medium (M) and high (H) doses—significantly restored BUN levels toward the sham control values.
Biochemical Restoration and Oxidative Stress Mitigation
The protective effect was further confirmed through a comprehensive panel of biochemical assays. RIRI typically depletes the body's natural antioxidant defenses while increasing oxidative damage markers. The combination treatment reversed these trends more effectively than either drug alone.
As illustrated in Figure 6, the co-treatment significantly lowered MDA levels (Panels A and B) and restored the activities of SOD (Panels C and D) and GSH-Px (Panel E). Notably, the levels of Nitric Oxide (NO) were also significantly increased in the co-treatment groups (Panel F). This is particularly important as NO promotes vasodilation and helps counteract the vasoconstriction associated with reperfusion injury.
Activation of the PI3K/NO Pathway
A key insight from the study is the upregulation of the PI3K (phosphatidylinositol-3 kinase) signaling pathway. Immunohistochemical analysis revealed that the combination treatment significantly increased PI3K protein expression in renal tissues. This activation is linked to the observed increase in NO production, suggesting that the EPO-Se synergy works through a multi-target mechanism involving both direct antioxidant activity and the activation of survival signaling pathways.
Conclusion
The co-administration of EPO and sodium selenite at an optimized 10:1 ratio provides superior protection against RIRI compared to monotherapy. By reducing oxidative stress and activating the PI3K/NO signaling pathway, this combination therapy offers a promising strategy for mitigating acute renal failure. Future studies should explore the long-term efficacy of this treatment and its potential translation into clinical practice, considering the complexities of human renal pathology.
Summary updated